Solitary fibrous tumour (SFT) is a rare subtype of soft tissue sarcoma (STS) that can occur in several anatomical sites, most frequently in middle-aged patients. Whereas most SFTs have an indolent course and can be cured by surgery, 15--20% of SFTs progress with either local recurrence or distant metastases ([@bib5]; [@bib14]). In addition to the classical SFT (CSFT), two more aggressive clinical-pathological variants of SFTs are currently recognised: malignant (MSFT) and dedifferentiated (DSFT), the latter showing a high-grade sarcoma overgrowth ([@bib32]; [@bib7]). We and other groups have recently described the activity of sunitinib malate (SM) ([@bib6]), in unresectable, progressive M/DSFT patients ([@bib18]; [@bib47], [@bib46]). Apart from being an anti-angiogenic drug, SM possesses immunomodulatory functions ([@bib25]; [@bib36]). The role of the immune system in controlling tumour growth has long been recognised and the immune contexture, defined by the frequency, type, functional polarisation and local distribution of immunocompetent cells at the tumour site, has been shown to impact tumour prognosis ([@bib15]; [@bib17]). Moreover, 'avoiding immune destruction\' has been recently listed as an emerging hallmark of cancer ([@bib19]; [@bib44]) and among the immune suppression mechanisms active in cancer patients, those mediated by Tregs and MDSCs strongly hinder the anti-tumour response in patients with cancer of different histology ([@bib12]; [@bib9]; [@bib33]). Little is presently known about the nature and features of the immune response to SFT, and no accurate histological description of local immunity exists for this STS. Moreover, the impact of anti-cancer therapies on the immunological status of SFT patients remains unexplored. Herein, we showed that the immunological profiles of CSFT, MSFT and DSFT patients, at the tumour site and in circulating PBMCs, revealed an immunosuppressive status. Our data demonstrated that SM treatment relieves systemic immunosuppression in PBMCs of M/DSFT patients, and at the tumour site it favoured the setting of an immune contexture with typical adaptive immunity traits. Altogether, these findings pave the way for the design of therapies that combine immune-based approach with anti-angiogenic treatment in SFT patients to achieve a more durable control of this aggressive disease.

Materials and methods
=====================

Immunohistochemistry and confocal analysis
------------------------------------------

Serial sections of 5-*μ*m thick formalin-fixed, paraffin-embedded (FFPE) SFT samples (*n*=19) were cut and processed for immunohistochemistry (IHC) or immunofluorescence staining (see [Supplementary materials and methods](#sup1){ref-type="supplementary-material"} for details). The clinical and pathological characteristics of each tumour are summarised in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}. All the tumour samples were analysed for the presence of the NAB2-STAT6 fusion as previously described ([@bib30]; [@bib39]) (see [Supplementary materials and methods](#sup1){ref-type="supplementary-material"}). The antibodies used for IHC and confocal analysis and their conditions of use are reported in [Supplementary Table S2](#sup1){ref-type="supplementary-material"}. Confocal microscopy was carried out using a Radiance 2100 microscope (Bio-Rad Laboratories, Hercules, CA, USA) equipped with a krypton/argon laser and a red laser diode. Evaluation of all IHC stains was performed by the Pathologist (SP) who scored the intensity of the staining using a scale from (−) no staining to (++++) very strong staining.

Blood sample collection and patient characteristics
---------------------------------------------------

This study was conducted in compliance with the Declaration of Helsinki and approved by the Ethical Committee of Fondazione IRCCS Istituto Nazionale dei Tumori, and all of the patients signed a written informed consent for the collection of blood samples. Blood samples were collected from SFT patients before and at different time points after initiating continuous treatment with anti-angiogenic therapy. Blood was also collected at the time of disease progression. Blood from age-matched healthy donors (HDs) was also obtained for control. PBMCs were isolated by Ficoll/Paque PLUS density gradient centrifugation within 2 h of the blood draw, as described elsewhere ([@bib4]). To avoid assay-to-assay variability, purified PBMCs were cryopreserved in liquid nitrogen for batch acquisition of Tregs and MDSCs based on phenotype and frequency. Immunological monitoring of circulating Tregs and MDSCs was conducted in a total of 17 SFT patients. The clinical characteristics of patients are reported in [Table 1](#tbl1){ref-type="table"}. The mean duration of the anti-angiogenic treatment was 6 months (range, 1--20); patients underwent disease assessment at baseline and after ∼1--2 months. Objective responses according to the Response Evaluation Criteria in Solid Tumors (RECIST) and tumour burden were determined by physician assessment of radiographs. Patients were treated until they experienced RECIST-defined disease progression or unacceptable toxicity.

SFT tumour dissociation and tumour-infiltrating lymphocytes analysis
--------------------------------------------------------------------

Tumour-infiltrating lymphocytes (TILs) were obtained from tumour sample of patients who underwent surgery by enzymatic and mechanic digestion using the gentleMACS Dissociator (Miltenyi, Bergisch-Gladbach, Germany). Briefly, tumour specimens were minced under sterile conditions into small pieces and digested over 1 h at 37 °C following the gentle MACS Dissociator protocol (Miltenyi). The resulting cell suspension was filtered through a 70-*μ*m mesh (BD Biosciences, San Jose, CA, USA), the red blood cells were lysed, and the cell suspension was washed with RPMI. Cells were stored in liquid nitrogen until use. For intracellular cytokine staining, patients\' TILs were seeded into 96-well round-bottom plates at 1.5 × 10^5^ cells per well in RPMI+10% human serum and stimulated overnight with PMA and Ionomycin (50 and 500 ng ml^−1^, respectively) plus GolgiStop (4 *μ*l 6 ml^−1^, BD Biosciences) at 37 °C. Tumour-infiltrating lymphocytes were stained for the cell-surface markers CD3, CD4 and CD8. The cells were then washed, fixed and permeabilised with Fix/Perm reagents (eBioscience, San Diego, CA, USA) following the manufacturer\'s protocol and then stained with a488-labelled anti-IFN-*γ* (BioLegend, San Diego, CA, USA), PE-labelled anti-Tbet (eBioscience) or PE-labelled anti-granzyme B (BD Biosciences). Dead cells were identified using the LIVE-DEAD Fixable Violet Dead Cell Stain Kit (Life Technologies, Carlsbad, CA, USA) according to the manufacturer\'s instructions and excluded from the analysis. The fluorescence intensity was measured using a Gallios (Beckman Coulter, Brea, CA, USA) flow cytometer and analysed using the Kaluza software (Tree Star Inc, Ashland, OR, USA).

Flow cytometry and intracellular cytokine staining
--------------------------------------------------

Treg and MDSC frequencies were determined by six-colour immunofluorescence staining of thawed PBMCs. The antibodies used are reported in [Supplementary Table S3](#sup1){ref-type="supplementary-material"}. Dead cells were identified using the LIVE-DEAD Fixable Violet Dead Cell Stain Kit (Life Technologies) and excluded from the analysis. For surface staining, cells were incubated with antibodies for 30 min at 4 °C after blocking non-specific antibody binding to the Fc receptors using FcR Blocking Reagent (Miltenyi). For Treg analysis, intracellular staining with APC-conjugated anti-Foxp3 (eBioscience) or the proper isotype control (rat IgG2a) was performed after fixation and permeabilisation of cells using an intracellular staining kit (eBioscience) according to the manufacturer\'s instructions. Intracellular staining was performed as follows. Lymphocytes activated overnight with anti-CD3/CD28 beads (DynaBeads CD3/CD28 T cell Expander, Invitrogen Dynal AS, Oslo, Norway) in the presence of 1 *μ*l ml^−1^ GolgiPlug (BD Biosciences) were stained for the cell-surface marker CD3. The cells were then washed, fixed and permeabilised with Cytofix/Cytoperm buffer (BD Biosciences) and stained with a488-labelled anti-IFN-*γ* (BioLegend), PE-labelled anti-IL-2 (BD Biosciences). Data acquisition was performed using a Gallios (Beckman Coulter) flow cytometer, and the Kaluza software was used for data analysis.

Intracellular protein kinase assay
----------------------------------

Cryopreserved PBMCs were thawed, washed and rested 2 h at 37 °C in RPMI containing 1% HS. Then, cells were incubated either without stimulation or stimulated with GM-CSF 10 ng ml^−1^, IL-4 100 ng ml^−1^, VEGF 50 ng ml^−1^ (all from Peprotech, Rocky Hill, NJ, USA) and IFN*α* 10 000 U ml^−1^ (Sigma-Aldrich, St Louis, MO, USA). Immediately after stimulation cells were fixed with pre-warmed BD Cytofix Buffer (BD Biosciences) for 10 min at 37 °C. After incubation cells were washed with PBS 1% FCS and then stained with anti-CD14 APC alexa750 (Beckman Coulter) and HLA-DR FITC (BD Biosciences) for 30 min and permeabilised with Perm Buffer III solution (BD Biosciences). Cell were then stained for intracellular expression of anti-pSTAT1 (Y701) Alexa Fluor 647, -pSTAT3 (Y705) Alexa Fluor 647, -pSTAT6 (Y641) PE and -pSTAT5 (Y694) PE (all from BD Bioscences). Data were acquired on a Gallios (Beckman Coulter) flow cytometer and analysed using the Kaluza software.

Arginase activity assay
-----------------------

Plasma from HDs and SFT patients was tested for arginase activity by measuring the production of [L]{.smallcaps}-ornithine from [L]{.smallcaps}-arginine, as previously reported ([@bib40]). In brief, a mix of 25 *μ*l of plasma and 25 *μ*l of buffer (Tris-HCl 50 n[M]{.smallcaps} pH 7.5 plus 10 m[M]{.smallcaps} MnCl~2~, Sigma-Aldrich) was heated at 55 °C for 20 min. Then, 150 *μ*l carbonate buffer (100 m[M]{.smallcaps}; Sigma-Aldrich) and 50 *μ*l [L]{.smallcaps}-arginine (100 m[M]{.smallcaps}; Sigma-Aldrich) were added and the mix incubated at 37 °C for 20 min. The hydrolysis of [L]{.smallcaps}-arginine was stopped with 750 *μ*l of glacial acetic acid. In all, 250 *μ*l of ninhydrin solution (2.5 g ninhydrin (Sigma-Aldrich); 40 ml H~3~PO~4~ 6 M; 60 ml glacial acetic acid) was added followed by incubation at 95 °C for 1 h. The amount (nmol) of [L]{.smallcaps}-ornithine was determined measuring the absorbance at 570 nm.

Statistical analysis
--------------------

The two-tailed unpaired Student\'s *t* test (with a 95% confidence interval (CI)) was used to compare groups, while the two-tailed paired Student\'s *t* test was used to analyse the effect of the treatments between different time points, as indicated in the figure legends. Statistical calculations were performed using the Prism5 software (GraphPad Software, La Jolla, CA, USA). *P*-values\<0.05 were considered as statistically significant. Error bars represent the standard error of the mean (s.e.m.).

Results
=======

Tumour-infiltrating immune cells in CSFT and M/DSFT
---------------------------------------------------

To gain insight into the immune contexture of SFTs, the presence and functional polarisation of tumour-infiltrating T cells and myeloid/macrophage cells were assessed by IHC analysis on a retrospective series of FFPE SFT specimens (*n*=11) collected from patients who did not receive anti-angiogenic therapy before surgery. This series of anti-angiogenic-naïve SFTs included three CSFTs, and five MSFTs and three DSFTs. [Supplementary Table S1](#sup1){ref-type="supplementary-material"} reports the histopathological features of the studied tumours. The majority of the analysed samples were negative or very poorly infiltrated with CD3^+^ T cells ([Figure 1A](#fig1){ref-type="fig"}). Only two cases (MSFT Tumour ID \#8 and DSFT Tumour ID \#9) displayed a remarkable positivity for CD3 staining ([Figure 1A](#fig1){ref-type="fig"}) that, however, was paralleled by a strong positivity for the Foxp3 nuclear marker, thus indicating enrichment in infiltrating Tregs ([Figure 1A](#fig1){ref-type="fig"}). In our samples, antibodies directed against the CD68 and CD163 markers did not stain tumour cells but did identify two different subgroups of tumour-associated macrophages (TAMs). All of the SFT cases displayed strong infiltration by CD163^+^ cells intermingled with the tumour cells, and the frequency of this myeloid cell type was further enhanced in tumours with a worse prognosis, namely M/DSFT samples. Conversely, CD68 staining was completely negative or revealed only few/scattered positive cells ([Figure 1A](#fig1){ref-type="fig"}). Confocal analysis, performed to better clarify the nature of the myeloid cells present in the M/DSFT microenvironment, showed that the majority of the CD163^+^ cells were positive for CD14, fitting with a pro-tumour, M2-TAM nature ([Figure 1B](#fig1){ref-type="fig"}, arrows) ([@bib28]). Moreover, a subset of CD163 single-positive cells was also detected ([Figure 1B](#fig1){ref-type="fig"}, circle). According to the literature, these cells might represent a subset of myeloid progenitors or immature cells ([@bib8]). Analysis of the granulocytic component was also performed and no evidence for a selective infiltration of this cell subset was evidenced. CD66b^+^ cells were in fact only occasionally found inside the tumour, with some positivity detected only in perivascular areas (see [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Collectively, the IHC and confocal analyses indicated poor T-cell infiltration and an immunological status skewed towards immune suppression in CSFT and in M/DSFT lesions.

Evidence of a distinct immune cell signature in M/DSFT lesions from SM-treated patients
---------------------------------------------------------------------------------------

Pro-angiogenic factors and abnormal tumour vasculature hamper the extravasation of immune cells into the tumour parenchyma and promote immune suppression ([@bib10]). Conversely, anti-angiogenic treatments, while normalising blood vessels, enhance immune infiltration, as recently shown in different animal models ([@bib45]; [@bib23]). In M/DSFT patients, we recently described the activity of SM, and we reported that SM led to vascular normalisation at the tumour site ([@bib46]). We thus explored the immune contexture in four M/DSFT lesions surgically removed from patients who received SM in neo-adjuvant setting.

All of these samples showed a high density of CD3^+^ TILs ([Figure 2A](#fig2){ref-type="fig"}), which included both CD4^+^ and CD8^+^ T cells. The intratumoral lymphocytes were mainly HLA-DR positive, and a consistent fraction of them also stained positive for granzyme B (GZMB) and T cell-restricted intracellular antigen (TIA-1, a cytotoxic granule-associated protein expressed by cytotoxic T cells and involved in the induction of apoptosis in CTL-sensitive targets) ([Figure 2A](#fig2){ref-type="fig"}). Thus, the CD3^+^ infiltrating cells were mainly activated T cells endowed with cytolytic potential. Moreover, their positivity for the nuclear transcription factor T-bet (immune cell-specific member of the T-box family of transcription factor coordinating type 1 immune responses) suggested enrichment in functional, Th-1-polarised T cells ([Figure 2A](#fig2){ref-type="fig"}). No Foxp3^+^ cells were detected ([Figure 2A](#fig2){ref-type="fig"}), indicating the absence of regulatory, suppressive T cells at the tumour site in post-SM M/DSFT patients. Concerning the monocyte/macrophage compartment, in addition to the CD163^+^CD68^−^ myeloid population ([Figure 3](#fig3){ref-type="fig"}), post-SM M/DSFTs displayed a strong positivity for intratumoral CD68^+^ myeloid cells ([Figure 3A](#fig3){ref-type="fig"}). On confocal analysis, these CD68^+^ cells co-expressed CD14 and represented a newly acquired population of macrophages rarely found in untreated tumours ([Figure 3Bb](#fig3){ref-type="fig"}). Moreover, these CD68^+^ macrophages displayed a typical round morphology, and double-immunofluorescence staining revealed co-expression of both the CD68 and HLA-DR markers ([Figure 3Bc](#fig3){ref-type="fig"}). These features are compatible with the M1 phenotype of activated macrophages. On IHC evaluation, all of the cases treated with SM showed signs of a pathologic response. Extensive areas of necrosis and tumour regression were observed in the proximity of the immune and inflammatory infiltration. Of note, around the area of tumour regression, CD8^+^ and CD4^+^ T cells were organised in clusters ([Figure 2B](#fig2){ref-type="fig"}). Altogether, the IHC results were consistent with an ongoing adaptive immunity in post-SM M/DSFTs. To strengthen this conclusion, *ex vivo* TILs were isolated from the excised naïve and post-SM MSFT (Patient ID \#13) specimens and tested *in vitro* for their immunological properties. T cells from post-SM lesions were found to contain functionally active CD4^+^ T cells producing IFN-*γ ex vivo* and CD8^+^ GZMB-positive T cells, representing effector cytotoxic T lymphocytes ([Figure 2C](#fig2){ref-type="fig"}).

Standard treatment for M/DSFT patients includes different regimens of cytotoxic chemotherapy (CT) associated or not with radiotherapy (RT). To verify whether modulation of the immune contexture at the tumour site also occurred in patients responding to CT, IHC analysis was performed in four M/DSFT tumour lesions surgically removed from patients who received CT/RT in neo-adjuvant setting. Weak/moderate CD3 infiltration and only few, spared CD68^+^ cells were detected in the two tumours post-CT (isofosfamide and/or epirubicin) plus RT (see [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}; Tumour IDs \#14 and \#15). The absence of CD68^+^ cells and very week CD3^+^ T-cell infiltration characterised the post-epirubicin (monotherapy) tumour (see [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}; Tumour ID \#13). Of note, in the tumour sample from a patient treated with doxorubicin and dacarbazine, moderate CD3^+^ infiltration, associated with a still week but more clusterised CD68^+^ positive infiltrate was detected in the proximity of areas showing signs of necrosis and tumour regression likely suggesting a possible engagement of the immune response.

Accumulation of immunosuppressive cells in the peripheral blood of SFT patients
-------------------------------------------------------------------------------

To evaluate the systemic immunological status of SFT patients, we explored the frequency of Tregs and MDSCs in the peripheral blood of a prospectively collected series of 17 SFT patients who included 5 patients with tumours classified as CSFTs, 6 as MSFTs and 6 as DSFTs ([Table 1](#tbl1){ref-type="table"}). PBMCs of HDs, matched for gender and age, were included as controls. Regulatory T cells, defined as CD25^hi^Foxp3^hi^ within a live-gated CD3^+^CD4^+^ cell population, were significantly expanded in M/DSFT patients compared with age-matched HDs (*n*=11) (*P*=0.0008, 1.04±0.65 *vs* 2.57±1.05); conversely, no statistically significant difference existed between HDs and CSFT patients ([Figure 4A](#fig4){ref-type="fig"}). The percentage of mMDSCs, first defined by our group as CD11b^+^CD14^+^HLADR^−/low^ ([@bib12]; [@bib20]; [@bib51]), was significantly higher in subjects with both CSFTs and M/DSFTs than in HDs (*P*=0.0398, 6.19±4.03; *P*\<0.0001, 13.88±6.56 *vs* 3.23±1.31, respectively) ([Figure 4B](#fig4){ref-type="fig"}). No difference in the percentages of Lin^−^HLADR^−^CD33^+^ MDSCs was detected between patients and HDs (data not shown). The overall frequency of CD3^+^CD4^+^ T cells and myeloid/monocyte CD14^+^CD11b^+^ cells did not differ significantly between patients and HDs ([Figure 4C and D](#fig4){ref-type="fig"}). Moreover, circulating CD3^+^ T cells from CSFT and M/DSFT patients were functionally impaired. [Figure 4E and F](#fig4){ref-type="fig"} shows that the frequency of CD3^+^ T cells that produced IFN-*γ* and IL-2 *ex vivo* was strongly reduced in patients\' PBMCs compared with HDs. Altogether, these phenotypic and functional assays suggested a status of systemic immunosuppression in SFT patients.

Anti-angiogenic therapy modulates peripheral immunosuppressive cells in patients with M/DSFT
--------------------------------------------------------------------------------------------

Our *in situ* analysis provided evidence that anti-angiogenic treatment reprogrammed the immune contexture of M/DSFTs and favoured the onset of an active T-cell immunity. To evaluate whether anti-angiogenic therapy also affected the systemic immunological status of patients with M/DSFT, we monitored the frequency of circulating Tregs and MDSCs in PBMCs from patients with M/DSFTs collected at different time points during SM (*n*=6 patients) or pazopanib (*n*=1 patient) therapy ([Table 1](#tbl1){ref-type="table"}). These anti-angiogenic drugs did not induce lymphopenia (data not shown). Interestingly, at the end of the second week of treatment (T15), the frequency of blood Tregs, evaluated within the CD3^+^CD4^+^ compartment ([Figure 5A](#fig5){ref-type="fig"}) or in the total number of live cells (see [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}), was significantly reduced (*P*=0.0020, 2.63±1.12 *vs* 1.41±0.75; *P*=0.0117, 0.57±0.37 *vs* 0.36±0.26). This effect was long lasting, and it was maintained for the duration of the treatment (*P*=0.0204, 1.41±0.75 *vs* 0.95±0.48; *P*=0.0403, 0.36±0.26 *vs* 0.22±0.14). The frequency of circulating mMDSCs, within the monocytic compartment ([Figure 5B](#fig5){ref-type="fig"}) or in the total number of live cells ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}), was significantly reduced at T15 (*P*=0.0040, 11.93±4.84 *vs* 6.27±5.52; *P*=0.0295, 2.72±2.18 *vs* 0.44±0.31). An increase in mMDSC frequency occurred in all of the patients at the time of disease progression although patients were still under drug treatment (*P*=0.0043, 6.27±5.52 *vs* 13.13±5.86; *P*=0.0030 0.44±0.31 *vs* 1.8±0.66) ([Figure 5B](#fig5){ref-type="fig"}). The MDSC population includes also gMDSCs. A consensus has been reached in considering human gMDSCs as CD14^−^CD66b^+^ and/or CD15+ activated neutrophils within total PBMCs or inside the Lin^−^HLADR^−^ fraction, displaying low density (thus being co-purified with PBMCs during blood centrifugation) and releasing arginase I in the circulation ([@bib52]; [@bib41]; [@bib2]). We thus assessed the frequency of this MDSC subtype in PBMC of M/DSFT by monitoring the CD66b^+^CD15^+^, or CD66b^+^Lin^−^HLA-DR^−^ cells as done in others published studies ([@bib52]; [@bib41]; [@bib2]; [@bib13]) ([Figure 5D](#fig5){ref-type="fig"}). Moreover, for each M/DSFT patient, the arginase activity was quantified in the plasma and plotted along the absolute neutrophil count ([Figure 5E](#fig5){ref-type="fig"}). With respect to HDs, M/DSFT patients displayed an enhanced frequency of gMDSCs ([Figure 5D](#fig5){ref-type="fig"}) and an increased number of neutrophils in the blood ([Figure 5E](#fig5){ref-type="fig"}), number that matched the higher plasma arginase activity. Frequency of gMDSCs, number of neutrophils and arginase activity were co-ordinately downmodulated by SM. However, similarly to Treg and at difference from mMDSCs, gMDSCs remained low all along the duration of SM treatment including at progressive disease ([Figure 5D and E](#fig5){ref-type="fig"}).

The functional assessment of the circulating CD3^+^ T cells, which was based on their capacity to produce IFN-*γ* and IL-2 *ex vivo* ([Figure 5F and G](#fig5){ref-type="fig"}), revealed that immunosuppression, present in patient PBMCs before anti-angiogenic treatment ([Figure 5F and G](#fig5){ref-type="fig"}, PRE), was quickly relieved at T15. At progression, with the increase in mMDSCs, T cells displayed again an impaired function characterised by a limited IFN-*γ* and IL-2 production, similarly to what was found for the pre-treatment T cells.

Three patients displaying a long lasting response to SM treatment ([Table 1](#tbl1){ref-type="table"}, Pts \#6a,8a,10a; SD or PR according RECIST evaluation after ⩾10 months) consistently showed a low level of mMDSCs, with values comparable to HDs ([Figure 6Aa](#fig6){ref-type="fig"}) and no evidence of CD3^+^ T-cell dysfunction in the peripheral blood could be detected in these SM-responsive patients ([Figure 6Ab and c](#fig6){ref-type="fig"}). Monocytic MDSCs from patients at time of disease progression were assessed for the activation of STAT-1, 3, 5 and 6 in response to the *ex vivo* cytokine stimulation. VEGF was unable to trigger STAT-3 phosphorylation in mMDSCs, likely as a result of the blocking activity exerted by SM. The other cytokines tested namely GM-CSF and IL-4, exerted their canonical activation pathways and induced STAT-5 and STAT-6 activation, respectively (data not shown). Conversely, these mMDSCs stimulated with IFN*α*, in addition to STAT-1 (data not shown), displayed a consistent phosphorylation of STAT-3. IFN*α*-dependent STAT-3 activation did not occurred in mMDSCs of HDs and SM-responsive patients ([Figure 6B and C](#fig6){ref-type="fig"}).

In summary, the analysis of the circulating immune cells in PBMCs from M/DSFT patients provided phenotypic and functional evidence of an immunosuppressive status that was quickly but temporary relieved by anti-angiogenic treatment. Suspension in the immunosuppression correlated with response to treatment.

Discussion
==========

To our knowledge, this is the first report that performed a detailed characterisation of the immunological status in the peripheral blood and at the tumour site of SFT patients and that considers the immune contexture of SFTs as a possible player in the response to therapy as well as in disease progression. Sunitinib malate exerts anti-tumour activity in M/DSFT ([@bib18]; [@bib47], [@bib46]) and patients achieving long-term tumour control have been reported ([@bib11]; [@bib26]). Besides the notion that immunity is emerging as a critical player in the response to treatment in cancer patients ([@bib53]), the rationale of assessing the role of the immune system in the efficacy of SM in SFTs stems from our previous observation that the levels of PDGFR*β* and/or VEGFR2 activation, evaluated by IHC in tumour lesions, did not fully account for the therapeutic response to treatment ([@bib46]).

The first interesting observation of our analysis was the presence of an immunosuppressed environment at the tumour site, characterised by a very dense infiltrate of myeloid cells and by the absence of granulocytic component. Myeloid cells, mostly CD68 negative, included CD163^+^CD14^+^CD68^−^ TAMs, interdispersed among cancer cells and with an elongated, ramified morphology compatible with M2-type macrophages ([@bib28]; [@bib24]; [@bib3]; [@bib22]), together with CD163^+^CD14^−^CD68^−^ cells likely representing immature myeloid-derived cells ([@bib24]; [@bib8]). Conversely, CD3^+^ lymphocytes were mainly absent, and when present, they were enriched in suppressive Foxp3^+^ Tregs. An immunosuppressive status was also detectable in the peripheral blood of SFT patients. In fact, circulating T cells were consistently functionally impaired, and a significant accumulation of mMDSCs and gMDSCs was observed in all the patients analysed. Notably, the increased frequency of circulating mMDSCs ([Figure 4B](#fig4){ref-type="fig"}) and gMDSCs (data not shown) seemed to correlate with tumour grade and disease aggressiveness, being already detectable in CSFT patients and reaching the highest level in M/DSFT patients. The more compromised immune status of these patients with advanced SFTs was further confirmed by the additional accumulation of circulating Tregs, which instead showed frequency close to normal values in patients with CSFTs. Altogether, this scenario reveals a previously unappreciated tumour-mediated immunosuppression in SFT patients and particularly in patients with M/DSFTs. This observation opens the question whether this immunosuppressive signature can be reversed by anti-angiogenic treatments and whether re-activated tumour immunity could be part of the response to treatment. Noteworthy, no information about the immunological effect of SM, as detected *in situ* at the tumour site in human setting, are available to date. Our IHC analysis showed that, as opposed to SM-naïve tumours, SM-treated lesions were all characterised by a remarkable CD3^+^ T-cell infiltration, with no Foxp3^+^ Treg, but that included Th1 and cytotoxic-competent CD4^+^ and CD8^+^ T cells. Moreover, TILs purified from an SM-treated MSFT lesion released e*x vivo* Th1-related cytokines and cytotoxic GZMB, thus supporting the local engagement of a functionally active host immune response. Activated T cells at the tumour site correlated with the concomitant presence of a new subset of CD68^+^ myeloid cells rarely found in untreated tumours. These CD68^+^ macrophages displayed the round-shape morphology typical of the M1 polarisation ([@bib29]), and expressed high level of HLA-DR. The pro-inflammatory and anti-tumour activity of CD68^+^ macrophages infiltrating post-therapy SFTs is also supported by their organisation in clusters around the areas of tumour regression and in close proximity with activated T lymphocytes. Since macrophages display an elevated grade of plasticity in response to external stimuli ([@bib27]), we may hypothesise that in SFTs, SM re-educated tumour-resident myeloid cells towards a more M1-related phenotype, or, alternatively, it recruited *ex novo* a new subset of monocytes/macrophages from peripheral blood.

Standard treatment for M/DSFT patients includes cytotoxic CT and/or RT. Evidence from the literature indicates that some CT regimens can be endowed with immunomodulatory activities ([@bib1]). Analysis of the immune contexture was thus performed in M/DSFT tumours obtained from cytotoxic responsive patients. Only very mild modulation of the immune infiltration was observed and this occurred mainly in those cases receiving RT, thus confirming previously published data ([@bib43]). Of note, two of the analysed tumours, one that showed very few infiltration of T cells and the absence of myeloid cells (Tumour ID \#13) and one treated with CT plus RT (Tumour ID \#14), derived from patients subsequently treated and responding to SM and whose post-SM tumours were here analysed ([Figure 2A and B](#fig2){ref-type="fig"}). At difference from the autologous post-CT counterpart, post-SM tumours displayed a profound change in the tumour immune microenvironment with huge CD3^+^ and CD68^+^ infiltrating cells organised in cluster and intermingled with tumour cells and areas of tumour necrosis. A coordinated presence of CD3^+^ and CD68^+^ cell infiltration at lower density but with distribution similar to that observed in post-SM tumours was found in the sample treated with doxorubicin and dacarbazine, thus possibly testifying an involvement of the immune system in the response to this CT regimen. In summary, a modulation of both myeloid and lymphoid immune infiltrate occurred in all the four post-SM tumours, thus indicating a tight association between immune system and response to SM. This was not the case for the post-CT samples. However, the here analysed post-CT tumours were derived from patients who underwent heterogeneous CT treatments. Moreover, for the doxorubicin and dacarbazine regimen, a single case was available for testing. Consequently, definitive conclusions on the involvement of immune system into CT-induced response deserve further investigation. This is expressly true for the doxorubicin and dacarbazine CT in view of the fact that a retrospective study recently reported this CT regimen as effective in M/DSFT ([@bib48]).

The ability of SM to interfere with myeloid cells, a property already suggested in other cancer patients ([@bib50]; [@bib25]), was further supported by our evidence that circulating mMDSCs and gMDSCs were significantly decreased in M/DSFT patients upon SM administration. The frequency of gMDSCs remained low and similar to the frequency found in HDs all along the duration of the treatment, including the time of progressive disease. Granulocytic MDSC behaviour thus overlapped that of Tregs and both these immunosuppressive cells might be considered as 'sensors/markers\' of the pharmacologic activity of SM. The SM effect on mMDSCs might be more associated with disease control. In fact the recruitment of a new subset of CD68^+^myeloid cells expressing the CD14 marker occurred at the tumour site of patients responding to SM. Moreover, while SM-responsive patients (*n*=3, 1 SD and 2 PR according RECIST evaluation, mean duration time of response ⩾10 months, [Table 1](#tbl1){ref-type="table"}) consistently displayed percentages of mMDSCs comparable to HDs, a rebound in the number of mMDSCs was observed at disease progression. Initial functional characterisation of mMDSCs analysed *ex vivo* from peripheral blood of patients progressing during SM treatment revealed the capacity of these cells to promote STAT3 phophorylation upon IFN*α* stimulation. The IFN*α*-mediated STAT3 phophorylation did not occur in mMDSCs of SM-responding patients. The role of STAT3 in the development and effector functions of MDSCs is well documented in murine setting ([@bib16]) and recently suggested as crucial also for human mMDSCs ([@bib37]). However, the functional implication of this alternative STAT3 activation in mMDSC biology, and most importantly, the effects of anti-angiogenic therapy on such a signalling pathway deserve to be further explored. Nevertheless, these data together with the mMDSC boost at progression suggest that SM treatment might induce/select a qualitatively different mMDSC population, possibly representing an immune-mediated mechanism of acquired resistance. This 'immunological resistance to treatment\' occurred only for the mMDSC compartment, as the SM-induced modulation of Treg and gMDSC frequency was detected in all the treated patients and it lasted for all the duration of the treatment.

In conclusion, our results shed light on a previously unappreciated phenomenon of immune dysfunction in this STS subtype and demonstrate that anti-angiogenic therapy opens a temporal window during which SFT patients regain normalisation in systemic myeloid differentiation status and T-cell functions thus, suggesting a contribution of the host immunity to the drug efficacy. Moreover, the rebound of circulating mMDSCs and impaired T-cell functions at tumour progression suggest that therapeutic strategies limiting residual myeloid suppressor activities ([@bib35]; [@bib21]; [@bib31]) and boosting tumour-specific immune responses represent a promising approach to improve the activity of anti-angiogenic treatment in SFT patients. Of note, the recent discovery that SFTs are marked by a tumour-specific chromosomal translocation (NAB2-STAT6) makes this tumour type an attractive target for active immunotherapy ([@bib30]; [@bib39]). In fact, the chimeric protein encoded by the recombinant *NAB2-STAT6* gene is a potential reservoir of unique tumour-specific antigens that are now considered as crucial in the design of an efficient personalised immunotherapy ([@bib34]; [@bib38]; [@bib49]).
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![**Analysis of tumour-infiltrating immune cells in M/DSFTs not treated with anti-angiogenic therapy.** Representative IHC stainings of two targeted therapy-naïve MSFT lesions (Tumour IDs \#5 and \#8). (**A**) (H&E) Haematoxylin and eosin staining. Images show MSFT lesions (ID \#5) with no or (ID \#8) moderate CD3 infiltration. (ID \#8) CD3^+^ T cells showed positivity for the Foxp3 nuclear marker. (Tumour IDs \#5 and \#8) Presence of a very high density of CD163-positive macrophages diffusely dispersed among the cancer cells. (ID \#5) Sparse or (ID \#8) absence infiltration of CD68^+^ macrophages. (**B**) (Tumour ID \#4) Double-label immunofluorescence staining for CD163 (green) and CD14 (red) macrophage markers. The arrow indicates CD163^+^CD14^+^ cells. The circle identifies CD163^+^ cells that do not express CD14.](bjc2014437f1){#fig1}

![**Analysis of infiltrating immune T cells in SM-treated M/DSFT lesions.** (**A**) Representative IHC stainings of an SM-treated MSFT lesion (Tumour ID \#13). (H&E) Haematoxylin and eosin stain. Staining for CD3^+^ (low and high magnifications), CD4^+^ and CD8^+^ T cells is showed. Representative images of the expression of T cell-associated markers HLA-DR, granzyme B (GZMB), T-bet and Foxp3 are reported. (**B**) IHC analysis of an SM-treated DSFT lesion (Tumour ID \#14) with evidence of tumour regression. In areas of tumour regression, T cells (CD3, CD4 and CD8) are organised in clusters. (**C**) Multi-parametric flow cytometry analysis of live lymphocytes from freshly dissociated naïve and SM-treated MSFT tumours (Tumour ID \#13). Expression levels of T-bet, IFN-*γ* and GZMB were evaluated by intracellular flow cytometry in CD3^+^ T cells. The gating strategy is reported.](bjc2014437f2){#fig2}

![**Analysis of infiltrating myeloid cells in SM-treated M/DSFT lesions.** Stainings representative of an SM-treated MSFT lesion (Tumour ID \#13). (**A**) IHC staining for the macrophage-associated markers CD163 and CD68 (low and high magnifications). (**B**) Double-label immunofluorescence staining and confocal analysis for (a) CD163 (green) and CD68 (red), (b) CD68 (green) and 14 (red), and (c) CD68 (green) and HLA-DR (red).](bjc2014437f3){#fig3}

![**Accumulation of immunosuppressive cells in the peripheral blood of SFT patients.** The frequencies of circulating Tregs and mMDSCs were monitored in the peripheral blood of CSFT (*n*=5) and M/DSFT (*n*=9) patients compared with healthy donors (HDs) (*n*=11). (**A**, **B**) Percentages of CD25^hi^Foxp3^hi^ cells (Tregs) and CD11b^+^CD14^+^HLADR^−/low^ cells (mMDSCs) defined within CD3^+^CD4^+^ T cells and CD14^+^CD11b^+^ cells, respectively. (**C**, **D**) Analysis of peripheral CD3^+^CD4^+^ T lymphocytes and CD11b^+^CD14^+^ myeloid cells within live-gated PBMCs. (**E**) IFN-*γ* and (**F**) IL-2 intracellular staining was performed on PBMCs after anti-CD3/CD28 overnight stimulation. Analysis was performed on CD3^+^-gated T cells. Each dot represents one patient. Statistical analysis: two-tailed unpaired Student\'s *t* test (95% confidence interval (CI)); only significant *P*-values are shown; bars indicate s.e.m.](bjc2014437f4){#fig4}

![**Anti-angiogenic therapy modulates immunosuppression in M/DSFT patients.** (**A**, **B**, **D** and **E**) Anti-angiogenic therapy modulates the frequencies of immunoregulatory cells in M/DSFT patients. PBMCs of M/DSFT patients collected at three time points during anti-angiogenic treatment were analysed for the frequency of (**A**) CD25^hi^Foxp3^hi^ cells (Tregs) in CD3^+^CD4^+^ T cells and (**B**) CD11b^+^CD14^+^HLADR^−/low^ cells (mMDSCs) in CD14^+^CD11b^+^cells. (**C**) Gating strategy for gMDSC determination; (**D**) gMDSCs detected as CD15^+^CD66b^+^ in live-gated PBMCs (black) or as CD66b^+^ cells within the Lin^−^HLA-DR^−^ fraction (light blue). (**E**) Absolute neutrophil count obtained by complete blood count (black dots), and arginase activity (red dots) evaluated as nmol ornithine per hour in 25 *μ*l of patient\'s plasma. Each dot represents one patient; bars indicate s.e.m. PRE, PBMCs collected prior anti-angiogenic therapy; T15, PBMCs collected at day 15 during therapy; at progression, PBMCs collected at the time of disease progression. (**F**, **G**) Increased levels of circulating mMDSCs correlated with decreased T-cell functionality. PBMCs from M/DSFT patients (*n*=7) collected at different time points during anti-angiogenic treatment (PRE; T15; at progression) were assayed for (**F**) IFN-*γ* and (**G**) IL-2 after anti-CD3/CD28 overnight stimulation. Analysis was performed on CD3^+^-gated T cells. The box plot depicts the median percentages of cytokine-positive CD3^+^ T cells. Statistical analysis: two-tailed paired Student\'s *t* test (95% confidence interval (CI)); only significant *P*-values are shown; bars indicate s.e.m.](bjc2014437f5){#fig5}

![**Modulation of mMDSCs in SM-treated M/DSFT patients.** (**A**) Patients responding to SM treatment had normal levels of mMDSCs and did not display dysfunctional T cells. (a) Frequency of CD11b^+^CD14^+^HLADR^−/low^ mMDSCs in PBMCs from M/DSFT patients treated with SM and displaying disease progression (Progression) or responsive to SM treatment (Response: 2 PR and 1 SD, duration of the response ⩾10 months). The same PBMCs as in (a) were evaluated for the (b) frequency of CD3^+^ T cells producing IFN-*γ* and (c) IL-2 after anti-CD3/CD28 overnight stimulation. (a) Each dot represents the data of a single patient. (b and c) Dot represents the mean value. (**B**) Representative histograms of pSTAT3 analyses in CD11b^+^CD14^+^HLADR^−/low^ cells (mMDSCs) with (black) and without (grey) IFN*α* stimulation (10 000 U ml^−1^ for 15 min at 37 °C). (**C**) Columns represent the IFNα-induced STAT3 activation in CD11b^+^CD14^+^HLADR^−/low^ cells of HDs (*n*=4), SM-responsive (*n*=3) and SM-progressive patients (*n*=6). Δ%pSTAT3 was calculated as: %pSTAT3 (IFN*α*)−%pSTAT3 (basal). Columns represent mean values; bars indicate s.e.m.](bjc2014437f6){#fig6}

###### Clinicopathologic characteristics of patients

  **Patient ID**                                               **Tumour site**    **Diagnosis**   **Drug treatment**[a](#t1-fn1){ref-type="fn"}   **Response to SM:** **RECIST evaluation**   **PFS (months)**
  ------------------------------------------------------------ ----------------- --------------- ----------------------------------------------- ------------------------------------------- ------------------
  1a                                                           Thigh                  CSFT                              −                                             −                              −
  2a                                                           Abdomen                CSFT                              −                                             −                              −
  3a                                                           Abdomen                CSFT                              −                                             −                              −
  4a                                                           Pelvis                 CSFT                              −                                             −                              −
  5a                                                           Thigh                  CSFT                              −                                             −                              −
  6a[b](#t1-fn2){ref-type="fn"}                                Pleura                 MSFT                             \+                                            PR                             12+
  7a[c](#t1-fn3){ref-type="fn"}                                Pleura                 MSFT                             \+                                            SD                              6
  8a[b](#t1-fn2){ref-type="fn"}                                Pleura                 MSFT                             \+                                            SD                              10
  9a                                                           Abdomen                MSFT                             \+                                            PD                             1.5
  10a[b,](#t1-fn2){ref-type="fn"}[d](#t1-fn4){ref-type="fn"}   Pelvis                 MSFT                             \+                                            PR                              20
  11a                                                          Pleura                 MSFT                             \+                                            SD                              5
  12a[c,](#t1-fn3){ref-type="fn"}[e](#t1-fn5){ref-type="fn"}   Pleura                 DSFT                \+[f](#t1-fn6){ref-type="fn"}           Not assessable[g](#t1-fn7){ref-type="fn"}          −
  13a[c](#t1-fn3){ref-type="fn"}                               Pleura                 DSFT                             \+                                            PD                              2
  14a[c](#t1-fn3){ref-type="fn"}                               Meninges               DSFT                             \+                                            PD                             1.5
  15a                                                          Pleura                 DSFT                             \+                                            PD                              2
  16a                                                          Peritoneum             DSFT                              −                                             −                              −
  17a                                                          Cerebellum             DSFT                              −                                             −                              −

Abbreviations: CSFT=classical solitary fibrous tumour; DSFT=dedifferentiated solitary fibrous tumour; MSFT=malignant solitary fibrous tumour; PD=progressive disease; PFS=progression-free survival; PR=partial response; RECIST=Response Evaluation Criteria in Solid Tumors; SD=stable disease; SM=sunitinib malate.

Age (median; range): 56; 35--76; Gender (n and %): M 29%, F 71% Male 5, Female 12.

Patients received 37.5 mg per die of SM.

PBMCs from the pre-treatment (PRE) period were not available for analysis.

Patients had undergone a previous CT regimen. A washout period of at least 15 days was respected before entering SM treatment and beginning blood draws.

For this patient, tumour removed after SM treatment was analysed by IHC and corresponded to Tumour ID \#13 in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}. TILs from Tumour ID \#13 were analysed *ex vivo* for their functional activity.

PBMCs at the time of progression were not available for analysis.

This patient received 800 mg per die of pazopanib.

Therapy interrupted due to toxicity.
